Can extracorporeal blood oxygenation combined with ozonization be used as an approved or effective treatment for severe hypoxemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Extracorporeal Blood Oxygenation and Ozonization (EBOO) Is Not an Approved or Evidence-Based Treatment for Severe Hypoxemia

Extracorporeal blood oxygenation combined with ozonization (EBOO) has no established role in treating severe hypoxemia and is not recognized by any major medical society or guideline as a valid therapeutic intervention. The term "extracorporeal blood oxygenation" in legitimate medical practice refers exclusively to extracorporeal membrane oxygenation (ECMO), which does not involve ozone therapy.

Critical Distinction: ECMO vs. EBOO

  • ECMO (Extracorporeal Membrane Oxygenation) is a guideline-supported, evidence-based rescue therapy for severe, potentially reversible cardiorespiratory failure when conventional therapies fail, as recommended by the American Thoracic Society 1

  • EBOO (Extracorporeal Blood Oxygenation and Ozonation) is an experimental ozone therapy technique with only case reports and small uncontrolled studies from 2000-2005, showing no evidence for respiratory failure treatment 2, 3

Evidence-Based Treatment: ECMO for Severe Hypoxemia

Indications for VV-ECMO in Severe Respiratory Failure

VV-ECMO should be considered when severe hypoxemia persists despite optimal conventional therapies, specifically when PaO₂/FiO₂ < 80 mmHg for ≥3 hours despite maximal ventilation strategies 1

  • Fast-entry criteria include PaO₂/FiO₂ < 70 mmHg for ≥3 hours despite FiO₂ > 0.70 and optimal PEEP 1

  • Slow-entry criteria include PaO₂/FiO₂ < 100 mmHg for ≥6 hours, plateau pressure > 28 cmH₂O for ≥6 hours despite lung-protective ventilation, or arterial pH < 7.20-7.25 for ≥6 hours 1

Pre-ECMO Optimization Requirements

Before considering ECMO, the following conventional rescue therapies must be optimized:

  • Lung-protective ventilation with tidal volume 4-6 mL/kg ideal body weight and plateau pressure < 30 cmH₂O 4, 1

  • Early prone positioning initiated within ≤48 hours of ARDS onset and maintained ≥12-16 hours daily when PaO₂/FiO₂ < 150 mmHg 1, 5

  • Neuromuscular blockade with cisatracurium for ≤48 hours during the first 48 hours of severe ARDS combined with deep sedation 1

  • Optimal PEEP titration ≥12 cmH₂O based on gas-exchange and hemodynamic response 1

Timing and Institutional Requirements

  • ECMO should be initiated within 7 days of respiratory failure onset for optimal outcomes; delay beyond 7-9 days of mechanical ventilation is associated with markedly worse survival 1

  • ECMO must only be performed at high-volume centers with ≥20-25 ECMO cases per year, as centers with higher volumes have significantly better outcomes 1

  • A multidisciplinary ECMO team must be available 24/7 with quality assurance review procedures 1

Mode Selection: VV-ECMO vs. VA-ECMO

  • VV-ECMO is indicated for isolated severe respiratory failure when cardiac function is adequate (norepinephrine ≤0.5 µg/kg/min and mean arterial pressure ≥65 mmHg) 1

  • VA-ECMO is reserved for combined cardiopulmonary failure with cardiogenic shock (reduced left-ventricular ejection fraction, norepinephrine >0.5 µg/kg/min, and right-ventricular overload with pulmonary artery systolic pressure >40 mmHg) 1

Why EBOO Has No Role in Respiratory Failure

Lack of Evidence for Respiratory Indications

  • The only published studies on EBOO describe its use in lipomas, Madelung disease, atherosclerotic vasculopathy, dyslipidemia, and sudden deafness—none involve respiratory failure or hypoxemia 2, 3

  • EBOO studies consist solely of case reports and small case series without controls, randomization, or peer-reviewed validation in high-quality journals 2, 3

Fundamental Mechanism Mismatch

  • EBOO treats only 250-4800 mL of blood per session over 1 hour with low-dose ozone (0.5-1 µg/mL), which cannot provide the continuous gas exchange required for severe hypoxemia 3

  • ECMO provides continuous oxygenation of 3-7 L/min of blood flow 24 hours per day, which is physiologically necessary for life support in severe respiratory failure 6

Common Pitfalls to Avoid

  • Do not confuse ozone therapy with legitimate extracorporeal oxygenation—the term "extracorporeal blood oxygenation" in evidence-based medicine refers exclusively to ECMO 1, 6

  • Do not delay ECMO referral in patients meeting criteria; transfer to an ECMO-capable center should occur within 7 days of respiratory failure onset 1

  • Do not attempt ECMO at low-volume centers—hospitals without ECMO capability must establish formal pathways for 24/7 mobile ECMO team retrieval 1

  • Recognize that ECMO itself carries significant risks, including bleeding complications in 37% of VV-ECMO patients and thrombotic events in 42%, requiring careful patient selection 1

References

1
Guideline

Indications for Extracorporeal Membrane Oxygenation (ECMO)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

2
Research

Extracorporeal blood oxygenation and ozonation (EBOO) in man. preliminary report.

The International journal of artificial organs, 2000

4
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

5
Guideline

Invasive Mechanical Ventilation in Severe Respiratory Distress

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

6
Research

Extracorporeal membrane oxygenation.

F1000prime reports, 2013

Related Questions

Is extracorporeal ozonation and oxygenation (ECO) effective in treating chronic kidney disease (CKD)?
What is the evidence for the use of ozonotherapy in medical practice?
What is the mixing point in Extracorporeal Membrane Oxygenation (ECMO)?
What is the role of Extracorporeal Membrane Oxygenation (ECMO) and ozonation in blood oxygenation?
Is there any benefit to ozone therapy?
How should I manage an adult patient with hypertension presenting with severe headache and otalgia?
What primary ethical framework does an Institutional Review Board use to evaluate a study involving participants with Alzheimer’s disease receiving fish oil?
Please provide a comprehensive clinical‑analytic evaluation, identifying the most likely primary source, constructing a causal chain, giving a prioritized differential diagnosis, distinguishing cause from effect, proposing a step‑by‑step treatment plan, suggesting further investigations, outlining risks of non‑treatment, and detailing short‑term (4‑8 weeks) and long‑term management.
A patient on aripiprazole (e.g., 2 mg daily for 2–4 weeks or 10 mg daily) develops new painless blurred vision and diplopia—what ocular side effects are associated with aripiprazole and how should they be managed?
For a 34‑year‑old man with polycythemia, chronic gastro‑esophageal reflux disease causing erosive gastritis/duodenitis, gallbladder sludge/chronic cholecystitis, pancreatic parenchymal changes and chronic bacterial prostatitis (based on the provided laboratory, endoscopic and ultrasound data), what is the most likely primary pathology, its pathogenic cascade, differential diagnosis, and what detailed short‑term (4‑8 weeks) and long‑term management plan should be recommended?
How should acute Bell’s palsy be managed, including timing of treatment, use of corticosteroids and antivirals, eye protection, facial exercises, follow‑up, and indications for further investigation or surgery?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question